Undifferentiated carcinoma of esophagus

Summary

Undifferentiated carcinoma of esophagus (MONDO:0018481) is a cancer and 2 clinical trials. Top therapeutic interventions include oxaliplatin and pralatrexate. A subtype of esophageal squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 2

Clinical features

Epidemiology

Prevalence records

24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.044	Europe	Validated
Annual incidence	<1 / 1 000 000	0.029	Austria	Validated
Annual incidence	<1 / 1 000 000	0.077	Belgium	Validated
Annual incidence	<1 / 1 000 000	0.027	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.006	Croatia	Validated
Annual incidence	1-9 / 1 000 000	0.115	Czech Republic	Validated
Annual incidence	<1 / 1 000 000	0.037	Estonia	Validated
Annual incidence	<1 / 1 000 000	0.002	Finland	Validated
Annual incidence	1-9 / 1 000 000	0.118	France	Validated
Annual incidence	<1 / 1 000 000	0.042	Germany	Validated
Annual incidence	<1 / 1 000 000	0.085	Iceland	Validated
Annual incidence	<1 / 1 000 000	0.012	Ireland	Validated
Annual incidence	<1 / 1 000 000	0.041	Italy	Validated
Annual incidence	<1 / 1 000 000	0.087	Latvia	Validated
Annual incidence	<1 / 1 000 000	0.021	Lithuania	Validated
Annual incidence	<1 / 1 000 000	0.038	Norway	Validated
Annual incidence	1-9 / 1 000 000	0.101	Poland	Validated
Annual incidence	<1 / 1 000 000	0.021	Portugal	Validated
Annual incidence	<1 / 1 000 000	0.082	Slovakia	Validated
Annual incidence	<1 / 1 000 000	0.013	Slovenia	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	undifferentiated carcinoma of esophagus
Mondo ID	MONDO:0018481
Orphanet	418951
NCIT	C27422
UMLS	C2188058
MedGen	412163
GARD	0021742
Anatomy (UBERON)	UBERON:0001043
Is cancer (heuristic)	yes

Also known as: esophageal undifferentiated carcinoma · esophagus undifferentiated carcinoma · oesophagus undifferentiated carcinoma · undifferentiated esophageal cancer · undifferentiated esophageal carcinoma

Disease family

This is a subtype of esophageal squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › esophageal squamous cell carcinoma › undifferentiated carcinoma of esophagus

Related subtypes (3): esophagus verrucous carcinoma, esophageal adenosquamous carcinoma, esophageal basaloid carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT01178944	PHASE2	COMPLETED	Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OXALIPLATIN	4	1
PRALATREXATE	4	1